Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 7008-7014

  Harjes, Stefan ^a   Solomon, William C ^a   Li, Ming ^a   Chen, Kuan Ming ^a,b   Harjes, Elena ^a   Harris, Reuben ^a   Matsuo, Hiroshi ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; NUCLEOTIDE; PENTANUCLEOTIDE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEAMINATION; DNA BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE MOTIF; PH; PRIORITY JOURNAL; PROTON TRANSPORT;

CATALYSIS; CELL LINE; CYTIDINE DEAMINASE; DNA, SINGLE-STRANDED; DNA, VIRAL; HISTIDINE; HIV INFECTIONS; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878537871     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03173-12     Document Type: Article

References (45)

1. Conticello SG. 2008. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9:229. doi:10.1186/gb-2008-9-6-229.
2. Goila-Gaur R, Strebel K. 2008. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51. doi:10.1186/1742-4690-5-51.
3. Harris RS, Hultquist JF, Evans DT. 2012. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 287:40875-40883.
4. Malim MH, Emerman M. 2008. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-398.
5. Smith JL, Bu W, Burdick RC, Pathak VK. 2009. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol. Sci. 30:638-646.
6. Haché G, Liddament MT, Harris RS. 2005. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280:10920-10924.
7. Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374-386.
8. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170.
9. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3'→5' on single-stranded DNA. Nat. Struct. Mol. Biol. 13:392-399.
10. Iwatani Y, Takeuchi H, Strebel K, Levin JG. 2006. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80:5992-6002.
11. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK. 2004. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:5652-5657.
12. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, Hayashi F, Kobayashi N, Yokoyama S, Takaku H, Katahira M. 2009. Structure, interaction and real-time monitoring of the enzymatic reaction of wildtype APOBEC3G. EMBO J. 28:440-451.
13. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M. 2008. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 15:1059-1066.
14. Rausch JW, Chelico L, Goodman MF, Le Grice SF. 2009. Dissecting APOBEC3Gsubstrate specificity by nucleoside analog interference. J. Biol. Chem. 284:7047-7058.
15. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435-442.
16. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
17. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF. 2010. Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285:16195-16205.
18. Chelico L, Sacho EJ, Erie DA, Goodman MF. 2008. A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J. Biol. Chem. 283:13780-13791.
19. Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, Nowarski R, Gross JD, Kotler M, Harris RS, Matsuo H. 2009. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 389:819-832.
20. Abramoff MD, Magalhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophotonics Int. 11:36-42.
21. Li M, Shandilya SM, Carpenter MA, Rathore A, Brown WL, Perkins AL, Harki DA, Solberg J, Hook DJ, Pandey KK, Parniak MA, Johnson JR, Krogan NJ, Somasundaran M, Ali A, Schiffer CA, Harris RS. 2012. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7:506-517.
22. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, Lyubchenko YL. 2011. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286:3387-3395.
23. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. 2010. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 17:222-229.
24. Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, Tomblingson GW, Lingappa JR. 2007. T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog. 3:1320-1334. doi:10.1371 /journal.ppat.0030135.
25. Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS. 2008. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82:2652-2660.
26. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H. 2008. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452:116-119.
27. Eisenthal R, Danson MJ, Hough DW. 2007. Catalytic efficiency and kcat/KM: a useful comparator? Trends Biotechnol. 25:247-249.
28. Chiba J, Kouno T, Aoki S, Sato H, Zhang J, Matsuo H, Inouye M. 2012. Electrochemical direct detection of DNA deamination catalyzed by APOBEC3G. Chem. Commun. 48:12115-12117.
29. Browne EP, Allers C, Landau NR. 2009. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387:313-321.
30. Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K. 2007. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81:13346-13353.
31. Carlow DC, Smith AA, Yang CC, Short SA, Wolfenden R. 1995. Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: mutation and rescue. Biochemistry 34:4220-4224.
32. Shandilya SM, Nalam MN, Nalivaika EA, Gross PJ, Valesano JC, Shindo K, Li M, Munson M, Royer WE, Harjes E, Kono T, Matsuo H, Harris RS, Somasundaran M, Schiffer CA. 2010. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18:28-38.
33. Shindo K, Li M, Gross PJ, Brown WL, Harjes E, Lu Y, Matsuo H, Harris RS. 2012. A comparison of two single-stranded DNA binding models by mutational analysis of APOBEC3G. Biology 1:260-276.
34. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, Sen U, Stevens RC, Goodman MF, Chen XS. 2008. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456:121-124.
35. Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT. 2009. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 284:22898-22904.
36. Carlow DC, Short SA, Wolfenden R. 1998. Complementary truncations of a hydrogen bond to ribose involved in transition-state stabilization by cytidine deaminase. Biochemistry 37:1199-1203.
37. Véliz EA, Easterwood LM, Beal PA. 2003. Substrate analogues for an RNA-editing adenosine deaminase: mechanistic investigation and inhibitor design. J. Am. Chem. Soc. 125:10867-10876.
38. Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M. 1996. A mammalian RNA editing enzyme. Nature 379:460-464.
39. O'Connell MA, Gerber A, Keller W. 1997. Purification of human doublestranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA. J. Biol. Chem. 272:473-478.
40. Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35:7096-7108.
41. Burnett A, Spearman P. 2007. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81:5000-5013.
42. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. 2005. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435:108-114.
43. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. 2009. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5:e1000330. doi:10.1371/journal.ppat .1000330.
44. Shlyakhtenko LS, Lushnikov AY, Miyagi A, Li M, Harris RS, Lyubchenko YL. 2012. Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry 51:6432-6440.
45. Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC. 2006. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281:38122-38126.